5-Jun-2026
No press releases found.
Market Chameleon (Thu, 20-Nov 6:51 AM ET)
The SPDR S&P Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index (the Index ). The S&P Biotechnology Select Industry represents the biotechnology segment of the S&P Total Market Index ( S&P TMI ). The S&P TMI is designed to track the broad U.S. equity market. The biotechnology segment of the S&P TMI comprises the Biotechnology sub-industry. The Index is modified equal weighted.
State Street SPDR S&P Biotech ETF trades on the ARCA stock market under the symbol XBI.
As of June 5, 2026, XBI stock price declined to $128.67 with 7,634,808 million shares trading.
XBI has a beta of 1.01, meaning it tends to be more sensitive to market movements. XBI has a correlation of 0.33 to the broad based SPY ETF.
XBI has a market cap of $7.78 billion. This is considered a Mid Cap stock.
In the last 3 years, XBI traded as high as $139.19 and as low as $63.80.
XBI has outperformed the market in the last year with a return of +56.4%, while the SPY ETF gained +25.6%. However, in the most recent history, XBI shares have underperformed the stock market with its stock returning +3.8% in the last 3 month period and -2.3% for the last 2 week period, while SPY has returned +8.5% and -1.1%, respectively.
XBI support price is $130.96 and resistance is $135.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XBI shares will trade within this expected range on the day.